Product Information
ENTRESTO SPRINKLE 15-16 MG PLT is a brand product labeled by Novartis Pharmaceuticals Corporation, priced at $11.6067 per EA under NDC 00078123820. Its NADAC has been published 63 times since Jul 23, 2025.
FDA first approved this application on Apr 12, 2024.
The High Outlier badge above means this manufacturer's average price in the Sacubitril and Valsartan market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
15; 16 mg/1; mg/1
Manufacturer
Novartis Pharmaceuticals CorporationNDC
00078123820
Classification
Brand
Dosage Form
PELLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
SACUBITRIL; VALSARTANApproval Type
New Drug (NDA)
FDA Application
NDA218591FDA Approved
4/12/2024
On Market Since
4/12/2024
Pharmacological Classes
Price Statistics
The NADAC for ENTRESTO SPRINKLE 15-16 MG PLT has been published 63 times since Jul 23, 2025, and over the history we have for it it has risen 2.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $11.6067 per EA |
|---|---|
| All-time high | $11.6485 (Jun 10, 2026) |
| All-time low | $11.2817 (Sep 17, 2025) |
| 52-week high | $11.6485 |
| 52-week low | $11.2817 |
| Median price | $11.6233 |
| Average price | $11.4917 |
| Largest weekly change | +3.0% (Jan 14, 2026) |
| Weeks tracked | 63 |
| Tracking since | Jul 23, 2025 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Sacubitril and Valsartan market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Novartis Pharmaceuticals Corporation manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Sacubitril and Valsartan market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Angiotensin 2 Receptor Blocker class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ENTRESTO SPRINKLE 15-16 MG PLT?
The current National Average Drug Acquisition Cost (NADAC) for ENTRESTO SPRINKLE 15-16 MG PLT, manufactured by Novartis Pharmaceuticals Corporation, is $11.6067 per EA (NDC 00078123820), effective Sep 30, 2026.
How has the price of ENTRESTO SPRINKLE 15-16 MG PLT changed over time?
Over the history we have for it, the NADAC for ENTRESTO SPRINKLE 15-16 MG PLT has risen 2.8%. It has been tracked across 63 weekly CMS publications since Jul 23, 2025.
What are the highest and lowest recorded NADAC prices for ENTRESTO SPRINKLE 15-16 MG PLT?
Since Jul 23, 2025, the NADAC for ENTRESTO SPRINKLE 15-16 MG PLT has ranged from a low of $11.2817 (Sep 17, 2025) to a high of $11.6485 (Jun 10, 2026), with a median of $11.6233 per EA.
Are there cheaper alternatives to ENTRESTO SPRINKLE 15-16 MG PLT?
No other NADAC-published product currently shares the active ingredient and strength of ENTRESTO SPRINKLE 15-16 MG PLT in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ENTRESTO SPRINKLE 15-16 MG PLT?
ENTRESTO SPRINKLE 15-16 MG PLT (NDC 00078123820) is labeled by Novartis Pharmaceuticals Corporation, and CMS classifies it as a brand product.